On the morning of November 5th, IVACTA Biotechnology (Shanghai) Co., Ltd. ("IVACTA Biotechnology"), an innovative company in the field of global in vivo cell therapy,Announced the completion of an angel round of financing exceeding RMB 100 million。This round of financing was led by Qiming Venture Partners, a global leading venture capital institution, with participation from B Capital, Apricot Capital, and Shunxi Fund.The financing funds will be mainly used for the iterative optimization of the core technology platform and the clinical translation and development of the first candidate product in the field of autoimmune diseases.
![]()
IVACTA Biotechnology was founded on June 25, 2025, as a spin-off of the in vivo CAR-T platform from Beijing Gracell Biomedicines Co., Ltd. (hereinafter referred to as "Gracell Biomedicines").IVACTA Biotechnology’s in vivo CAR-T therapy, developed based on targeted LNP delivery systems, focuses on bringing revolutionary treatments to hematologic tumors and autoimmune diseases., CAR expression can be directly completed within the patient's T cells. Patients no longer need to undergo the cell separation, expansion, and lymphodepletion pretreatment processes required in traditional autologous CAR-T therapy. This addresses the three core pain points of autologous CAR-T therapy — "high cost, long cycle, and significant toxicity" — at their root. It is expected to significantly shorten the treatment cycle, enable the evolution of cell therapy into off-the-shelf drugs, and greatly improve patient accessibility.At the same time, IVACTA Biotechnology's targeted LNP delivery system stands out in terms of precision, safety, and production compatibility. It enhances T-cell targeting efficiency through a unique technical approach, effectively reduces off-target risks, and adapts to scalable preparation. The self-developed targeting technology achieves efficient T-cell activation and long-term CAR expression, demonstrating excellent B-cell depletion effects in multiple preclinical models with good safety upon repeated dosing.The first candidate product has entered clinical trials and has already obtained positive preliminary human data.Dr. Yarong Liu, Founder and CEO of IVACTA Biotechnology, stated"Thanks to the trust from Qiming Venture Capital and other investors. As a深耕者 in China's cell therapy field, our team has always been committed to filling unmet clinical needs through technological innovation. IVACTA Biotechnology's in vivo CAR-T solution is an important step in advancing cell therapy towards 'off-the-shelf' and 'accessibility'. This round of financing will accelerate the clinical validation of IVACTA Biotechnology and its in vivo CAR-T pipeline. In the future, we will continue to uphold the concept of 'insight into demand, independent innovation', striving to bring more innovative treatment options to patients."Scan the WeChat QR code, add the editor of the Biological Products Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!All articles reproduced in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reprinted can contact us (cbplib@163.com), and we will immediately delete the content. All articles represent the views of the author, not this site.
